Liwei Zhao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/37039/publications.pdf

Version: 2024-02-01

21 papers	1,225 citations	687220 13 h-index	713332 21 g-index
22 all docs	22 docs citations	22 times ranked	1432 citing authors

#	Article	IF	Citations
1	Assessment of immunological memory formation in vivo. Methods in Cell Biology, 2022, , .	0.5	0
2	Assessment of type I interferon responses as a feature of immunogenic cell death. Methods in Cell Biology, 2022, , 135-143.	0.5	4
3	PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. OncoImmunology, 2022, 11, .	2.1	25
4	Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response. Cell Death and Disease, 2021, 12, 6.	2.7	21
5	Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score. Cancer Management and Research, 2021, Volume 13, 6473-6487.	0.9	5
6	Quantitation of calreticulin exposure associated with immunogenic cell death. Methods in Enzymology, 2020, 632, 1-13.	0.4	16
7	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. Molecular Cell, 2020, 77, 748-760.e9.	4.5	77
8	Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death and Disease, 2020, 11, 1013.	2.7	466
9	Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis. OncoImmunology, 2020, 9, 1792037.	2.1	17
10	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. OncoImmunology, 2020, 9, 1789284.	2.1	4
11	Secreted calreticulin mutants subvert anticancer immunosurveillance. OncoImmunology, 2020, 9, 1708126.	2.1	11
12	Crizotinib â€“ a tyrosine kinase inhibitor that stimulates immunogenic cell death. OncoImmunology, 2019, 8, e1596652.	2.1	25
13	A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. OncoImmunology, 2019, 8, 1606665.	2.1	12
14	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	5.8	189
15	Methods for measuring HMGB1 release during immunogenic cell death. Methods in Enzymology, 2019, 629, 177-193.	0.4	7
16	Epigenetic anticancer agents cause HMGB1 release in vivo. OncoImmunology, 2018, 7, e1431090.	2.1	12
17	eIF2Î± phosphorylation is pathognomonic for immunogenic cell death. Cell Death and Differentiation, 2018, 25, 1375-1393.	5.0	162
18	Identification of pharmacological inhibitors of conventional protein secretion. Scientific Reports, 2018, 8, 14966.	1.6	21

#	Article	IF	Citations
19	Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. EMBO Journal, 2018, 37, .	3.5	81
20	Redaporfin induces immunogenic cell death by selective destruction of the endoplasmic reticulum and the Golgi apparatus. Oncotarget, 2018, 9, 31169-31170.	0.8	15
21	Identification of pharmacological agents that induce HMGB1 release. Scientific Reports, 2017, 7, 14915.	1.6	37